Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
May 10, 2021 08:30 ET
|
Cellectar Biosciences
Initiated pivotal study of CLR 131 in Waldenstrom’s macroglobulinemia (WM)Received European Orphan Drug Designation for CLR 131 in WM Strong cash position of approximately $54 million providing cash...
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
April 27, 2021 08:39 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Participate at Upcoming Institutional Investor Conferences
March 11, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
March 09, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Participate at Upcoming Institutional Investor Conferences
March 05, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
March 02, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Present at BIO CEO & Investor Digital Conference
February 10, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
January 27, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
January 12, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
December 28, 2020 16:05 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...